1. Medicine

Category Archives: Medicine

Testimonial by Keith Radbill, N.P. – American Academy of Procedural Medicine Training – Video

Posted on by


Testimonial by Keith Radbill, N.P. - American Academy of Procedural Medicine Training
aaopm.com video on Keith Radbill, who attended the American Academy of Procedural Medicine Training Program in Orlando, Florida about botox and gave a little...

By: AAOPM

Originally posted here:

Testimonial by Keith Radbill, N.P. - American Academy of Procedural Medicine Training - Video

S&N Pays $1.5B For Sports Medicine Specialist ArthroCare

Posted on by

NEW YORK (The Deal) -- The U.K.'s Smith & Nephew hopes to get a leg up in the fast-growing sports medicine sector through the $1.5 billion acquisition of Nasdaq-listed ArthroCare (ARTC) which counts One Equity Partners LLC as its largest shareholder.

The London-based buyer said Monday it agreed to offer $48.25 a share in cash for Austin, Texas-based ArthroCare. The offer price is price is 6.3% above the target's closing share price Friday on Nasdaq, and the $1.5 billion enterprise value, which is net of roughly $200 million of cash, represents a multiple of 15.7 times adjusted 2012 Ebitda, according to Smith & Nephew.

Smith & Nephew shares added 1.4% in London Monday morning to trade at 888 pence, for a total market value of about 2.92 billion ($4.77 billion). Smith and Nephew is looking to the acquisition to bolster its offerings in noninvasive sports medicine.

"This is a great deal that rebalances Smith & Nephew in areas of higher growth," said Smith & Nephew CEO Olivier Bohuon on a conference call.

Original post:

S&N Pays $1.5B For Sports Medicine Specialist ArthroCare

Chemical stem cell signature predicts treatment response for acute myeloid leukemia

Posted on by

PUBLIC RELEASE DATE:

3-Feb-2014

Contact: Kim Newman sciencenews@einstein.yu.edu 718-430-3101 Albert Einstein College of Medicine

February 3, 2014 (Bronx, NY) Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical "signature" in blood-forming stem cells that predicts whether patients with acute myeloid leukemia (AML) will respond to chemotherapy.

The findings are based on data from nearly 700 AML patients. If validated in clinical trials, the signature would help physicians better identify which AML patients would benefit from chemotherapy and which patients have a prognosis so grave that they may be candidates for more aggressive treatments such as bone-marrow transplantation. The paper was published today in the online edition of the Journal of Clinical Investigation.

Sparing Patients from Debilitating Side Effects

According to the American Cancer Society, AML accounts for nearly one-third of all new leukemia cases each year. In 2013, more than 10,000 patients died of AML.

"AML is a disease in which fewer than 30 percent of patients are cured," said co-senior author Ulrich Steidl, M.D., Ph.D., associate professor of cell biology and of medicine and the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research at Einstein and associate chair for translational research in oncology at Montefiore. "Ideally, we would like to increase that cure rate. But in the meantime, it would help if we could identify who won't benefit from standard treatment, so we can spare them the debilitating effects of chemotherapy and get them into clinical trials for experimental therapies that might be more effective."

Analyzing Methylation Patterns

The Einstein study focused on so-called epigenetic "marks" chemical changes in DNA that turn genes on or off. The researchers focused on one common epigenetic process known as methylation, in which methyl (CH3) groups attach in various patterns to the genes of human cells. Researchers have known that aberrations in the methylation of hematopoietic, or blood-forming, stem cells (HSCs) can prevent them from differentiating into mature blood cells, leading to AML.

Read more from the original source:

Chemical stem cell signature predicts treatment response for acute myeloid leukemia

Medicine claim in Telford drink drive case

Posted on by

A Telford man claimed cough medicine was the reason he was over the drink-drive limit.

Andrew Hutton John Mitchell, of Hill Road, Overdale, told Telford Magistrates Court he had drunk two cans of lager, but had also taken cough medicine for an illness.

Mitchell, 38, was spotted by police on Oakworth Close in Hadley at 1am on January 20 when they saw the green Ford Focus he was driving veering across the road.

He was found to have 62 microgrammes of alcohol in 100 millilitres of breath the legal limit is 35.

He admitted driving a motor vehicle while over the legal alcohol limit.

Mrs Kate Price, prosecuting, told the court yesterday Mitchell was immediately pulled over by officers and was unsteady on his feet and his speech was slurred.

She said: He told officers I know I will be over, Ive had a stressful night.

Mitchell, who represented himself in court, said: I know what I did was wrong, I only had two cans but I was poorly so I had been drinking cough medicine.

Mitchell was disqualified from driving for 36 months, fined 200 and ordered to pay prosecution costs of 85 as well as a victim surcharge of 20.

He said: Sorry is all I can say.

See more here:

Medicine claim in Telford drink drive case

Assassin’s Creed IV: Black Flag – Gameplay Walkthrough Part 15 – Securing Medicine – Video

Posted on by


Assassin #39;s Creed IV: Black Flag - Gameplay Walkthrough Part 15 - Securing Medicine
Please remember to leave a like and/or Subscribe it helps out a lot 🙂 Subscribe: http://www.youtube.com/subscription_center?add_user=mrmanpacster Getting me...

By: MrManPacster

See the rest here:

Assassin's Creed IV: Black Flag - Gameplay Walkthrough Part 15 - Securing Medicine - Video

Vet-Stem, Inc. Proudly Sponsors the Regenerative Medicine Sessions at the Fourth World Veterinary Orthopaedic Congress

Posted on by

Poway, California (PRWEB) January 31, 2014

Vet-Stem, Inc., the leading Regenerative Veterinary Medicine company is proud to announce their co-sponsorship of the Veterinary Orthopedic Society/North American Veterinary Regenerative Medicine Association Regenerative Medicine sessions at the fourth World Veterinary Orthopaedic Congress. The Congress will be taking place at the Beaver Run Resort in Breckenridge, Colorado from March 1st through the 8th of this year.

Vet-Stem has always supported the Veterinary Orthopedic Society (VOS) and the North American Veterinary Regenerative Medicine Association (NAVRMA) in the promotion of education and new information in the veterinary industry. The VOS/NAVRMA Regenerative Medicine sessions at the Congress will be discussing and presenting topics concerning sources of stem cells as well as use of stem cells and other cellular therapies for ligament, tendon, and cartilage injuries in dogs and horses.

Robert Harman, DVM, Founder and CEO Vet-Stem spoke recently at the NAVRMA Conference in Atlanta, Georgia. His presentation titled One Medicine and Collaboration for Rapid Development of Cell Therapy showed a model and examples of collaborations between commercial, academic, human and veterinary groups to the betterment of all medical progress. He illustrated how veterinary stem cell medicines have impacted the clinical progress of human stem cell medicines development.

Dr. Harman pulls from his biotechnology and veterinary experience to help Vet-Stem perfect the clinical application of regenerative therapies for various types of injuries, illnesses, and other healing-promoting applications. Vet-Stem is leading in the development for regenerative medicine in the veterinary field, with over 10,000 animals treated in the last 10 years.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

See the article here:

Vet-Stem, Inc. Proudly Sponsors the Regenerative Medicine Sessions at the Fourth World Veterinary Orthopaedic Congress


  1. Medicine